Security
CV · CapsoVision, Inc
CVNASDAQCommon stockCurrentCIK 1378325Updated Sep 27, 2026
Name history
Capso Vision Inc · through Feb 21, 2014
CV price & chart
Loading TradingView…
NASDAQ:CV on TradingView ↗About the company
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.
In the news
Recent filings
4 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
EFFECT filing
424B5 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
S-3 filing
10-Q filing
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition
Items 1.01, 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 18,164,000Source | 16,803,000Source |
| Property, Plant and Equipment, NetUSD | 611,000Source | 720,000Source |
| Current assets: | ||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,498,000Source | 2,001,000Source |
| Inventory, NetUSD | 2,987,000Source | 2,629,000Source |
| Assets, CurrentUSD | 16,669,000Source | 14,847,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,072,000Source | 898,000Source |
| Operating Lease, Right-of-Use AssetUSD | 843,000Source | 1,195,000Source |
| Other Assets, NoncurrentUSD | 41,000Source | 41,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 4,904,000Source | 2,688,000Source |
| Stockholders’ equity: | ||
| Common Stock, Value, IssuedUSD | 47,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 168,878,000Source | 838,000Source |
| Retained Earnings (Accumulated Deficit)USD | -155,665,000Source | -130,350,000Source |
| Stockholders' Equity Attributable to ParentUSD | 13,260,000Source | -129,510,000Source |
| Liabilities and EquityUSD | 18,164,000Source | 16,803,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 4,427,000Source | 1,801,000Source |
| Operating Lease, Liability, CurrentUSD | 410,000Source | 351,000Source |
| Accounts Payable, CurrentUSD | 1,143,000Source | 749,000Source |
| Operating Lease, Liability, NoncurrentUSD | 477,000Source | 887,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 2,697,000Source | 569,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 216,000Source | 206,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 826,000Source | 156,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 478,000Source | 176,000Source |
| Increase (Decrease) in InventoriesUSD | 358,000Source | 434,000Source |
| Increase (Decrease) in Accounts PayableUSD | 376,000Source | 388,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -22,864,000Source | -20,091,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -90,000Source | -153,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 90,000Source | 153,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 23,604,000Source | 15,074,000Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,000Source | 0Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 826,000Source | 156,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 193,000Source | -93,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 173,000Source | -103,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -1,000Source | 0Source |
| General and Administrative ExpenseUSD | 6,849,000Source | 4,207,000Source |
| Income Tax Expense (Benefit)USD | 24,000Source | 11,000Source |
| Net Income (Loss) Attributable to ParentUSD | -25,315,000Source | -19,898,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,315,000Source | -19,898,000Source |
| Nonoperating Income (Expense)USD | 225,000Source | 30,000Source |
| Operating ExpensesUSD | 32,689,000Source | 26,294,000Source |
| Other Nonoperating Income (Expense)USD | -44,000Source | 4,000Source |
| Proceeds from Stock Options ExercisedUSD | 158,000Source | 75,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 13,554,000Source | 11,756,000Source |
| Cost of RevenueUSD | 6,381,000Source | 5,379,000Source |
| Operating Income (Loss)USD | -25,516,000Source | -19,917,000Source |
| Other Nonoperating Income (Expense)USD | -44,000Source | 4,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -25,291,000Source | -19,887,000Source |
| Income Tax Expense (Benefit)USD | 24,000Source | 11,000Source |
| Net Income (Loss) Attributable to ParentUSD | -25,315,000Source | -19,898,000Source |
| Earnings Per Share, BasicUSD per share | -1.03Source | -9.85Source |
| Earnings Per Share, DilutedUSD per share | -1.03Source | -9.85Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 24,555,381Source | 2,020,077Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 24,555,381Source | 2,020,077Source |
| Additional Financial Items | ||
| Current Income Tax Expense (Benefit)USD | 24,000Source | 11,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 193,000Source | -93,000Source |
| General and Administrative ExpenseUSD | 6,849,000Source | 4,207,000Source |
| Gross ProfitUSD | 7,173,000Source | 6,377,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -24,424,000Source | -19,220,000Source |
| Investment Income, NetUSD | 269,000Source | 26,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,315,000Source | -19,898,000Source |
| Nonoperating Income (Expense)USD | 225,000Source | 30,000Source |
| Operating ExpensesUSD | 32,689,000Source | 26,294,000Source |
| Research and Development ExpenseUSD | 18,310,000Source | 15,120,000Source |
| Selling and Marketing ExpenseUSD | 7,530,000Source | 6,967,000Source |
Offerings
Registration 333-295153
Registration 333-287148
- Gross proceeds
- 27500000.0
- Net proceeds
- 25575000.0
- Deal price
- 5.0
- Shares
- 5500000
- Offering price
- $5.00
- Ticker
- CV
Filing attachments
cv-20260702xex991.htm · 8-K · 2026-07-02
EX-99.1 4 cv-20260702xex991.htm EX-99.1 Document Exhibit 99.1 CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors Longtime Clinical Advisor and Capsule Endoscopy Pioneer Joins Board as Company Advances AI-Enabled Capsule Endoscopy Platform SARATOGA, Calif., July 2, 2026 - CapsoVision, Inc. (Nasdaq: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, announced the appointment of …
Read attachment ↗cv-20260320xex991.htm · 8-K · 2026-03-20
EX-99.1 7 cv-20260320xex991.htm EX-99.1 Document Exhibit 99.1 CapsoVision Announces $14 Million Private Placement Financing Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 - CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity fina…
Read attachment ↗cv-20251229xex991.htm · 8-K · 2025-12-29
EX-99.1 2 cv-20251229xex991.htm EX-99.1 Document Exhibit 99.1 CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus® Company Preparing to Commence Commercialization Following U.S. FDA 510(k) Clearance SARATOGA, Calif., December 29, 2025 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application …
Read attachment ↗cv-20251110xex991.htm · 8-K · 2025-11-10
EX-99.1 2 cv-20251110xex991.htm EX-99.1 Document Exhibit 99.1 CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwide SARATOGA, Calif., November 10, 2025 -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule end…
Read attachment ↗cv-20251103xex991.htm · 8-K · 2025-11-03
EX-99.1 2 cv-20251103xex991.htm EX-99.1 Document Exhibit 99.1 CapsoVision Appoints David Garcia as Senior Vice President of Finance Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growth SARATOGA, Calif., November 3, 2025 -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the appointment of David Garcia…
Read attachment ↗cv-20250715xex41.htm · 8-K · 2025-07-18
EX-4.1 2 cv-20250715xex41.htm EX-4.1 Document Exhibit 4.1 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING JULY 3, 2025, WHICH IS THE COMMENCEMENT DATE OF SALES IN THE OFFERING (TH…
Read attachment ↗